Long-term access to remibrutinib for skin or allergy patients
Treatments studied
This trial provides ongoing access to remibrutinib for people who were previously in a Novartis study and are still benefiting from the drug. It is for those who cannot get the marketed version yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed treatment in a prior Novartis study of remibrutinib for a skin or allergy condition.
- You are still benefiting from remibrutinib and your doctor thinks you should continue.
- You cannot get the marketed form of remibrutinib through local programs or insurance.
- You did not stop treatment early in the earlier study.
- You are not taking any prohibited medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called remibrutinib to see if it can reduce allergic reactions to peanuts, milk, or eggs. It is for people aged 12 to 65 who have been diagnosed with a food allergy and are willing to participate in food challenges.
This study tests an investigational medicine (remibrutinib) for people with severe itching that has no known cause. It may help reduce the itch when moisturizers haven't worked.
This study tests the long-term safety and effectiveness of remibrutinib for people with moderate to severe hidradenitis suppurativa (HS) who have already completed a 68-week treatment period in a related study.
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
This trial tests an oral drug called remibrutinib to see if it can help people with relapsing or progressive multiple sclerosis. It uses brain scans (MRI) to track how well the drug works.
This study follows people with chronic hives (CSU) who start taking remibrutinib as part of their normal care. It looks at how well the medicine works in real life over 24 months.
Hear when a new Indication of the Parent Protocol trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.